Eternal Search is a live longevity-focused funding and intelligence platform operated by Open Longevity (California 501(c)(3) nonprofit) that claims to reduce manual opportunity discovery by using AI-assisted curation, verification, deduplication, and relevance scoring across grants, fellowships, infrastructure support, investors, and related field signals. The strongest evidence supports it as an operating research-and-funding infrastructure product with public listings, basic traction metrics, and an API-oriented roadmap; the weakest point is that its core accuracy, coverage, and time-saving claims are self-described rather than independently validated.
Comprehensive brief
Hypothesis
A continuously updated, AI-assisted funding intelligence system can materially reduce missed opportunities and search overhead for longevity and adjacent research teams if it can verify deadlines and URLs, remove duplicates, and rank opportunities by scientific focus, career stage, and geography better than manual search or generic keyword tools.
Mechanism
The platform’s claimed mechanism is ongoing web discovery plus structured extraction into dossiers, followed by verification, deduplication, and semantic relevance scoring. It also claims to maintain shared discovery data, private team workspaces, API access, and ratings that update as new evidence arrives, making funding discovery more like a maintained knowledge system than a static grant list.
Approach
Eternal Search’s approach is applied infrastructure: a public catalogue of opportunities, deadline tracking, AI-curated ranking, institutional/API workflow integration, and investor or organisation intelligence modules. The practical emphasis is not on producing new biology or therapeutics, but on helping scientists, startups, nonprofits, and funders navigate fragmented funding and field information more efficiently.
Status
The project appears to be live rather than conceptual. Evidence from its own pages shows a public-facing product with 646 grants in the catalogue, 53 open grants, 21 companies rated, 2 projects rated, 94 concepts in the database, and 7 upcoming events, alongside claims of API access and private workspaces. It is based in Sherman Oaks, California, positioned as global in scope, and is seeking grant support for server, compute, and engineering continuity, which suggests the platform exists but is still financially and operationally scaling.
Success criteria
The clearest success test is operational, not rhetorical: users should find more relevant opportunities with fewer false positives, fewer duplicates, and fewer stale or incorrect deadlines than they would through manual search. Additional credible success signals would be sustained catalogue freshness, transparent verification accuracy, measurable reduction in search time for teams, successful institutional/API adoption, and evidence that the matching system generalizes beyond longevity into adjacent fields without degrading precision.
Scientific panel
Mechanism plausibility62
The proposed mechanism is operational rather than biological: continuous web discovery, structured extraction, verification, deduplication, and semantic relevance scoring should plausibly reduce search overhead if implemented well. The evidence shows the platform claims these functions and has a live public catalogue, but there is no independent evidence that its verification, ranking, or deduplication outperform manual search or generic tools.
Evidence base45
The evidence base supports existence and basic activity: public pages report 646 total grants, 53 open grants, 21 rated companies, 2 rated projects, 94 concepts, 7 events, news pages, an API privacy policy, and individual grant dossiers. However, most performance claims come from Eternal Search itself, with no user study, benchmark dataset, audit of stale listings, precision/recall analysis, or third-party adoption evidence in the provided material.
Methodological rigor32
The project describes verification before publication, deadline and URL rechecking, inactive-program handling, private workspaces, and API logging, which are reasonable product controls. But the fetched evidence does not specify sampling procedures, error rates, inter-rater checks, evaluation metrics, statistical tests, preregistered success criteria, or controlled comparisons against manual workflows.
Reproducibility28
There is evidence of repeatable-looking public outputs, including grant records and news/intelligence pages, but no independent replication, external audit, open benchmark, or documented reproduction of matching and verification accuracy. The API and public catalogue could enable future reproducibility, yet the provided evidence does not show that outside users can reproduce the platform's ratings or relevance scores.
Novelty55
A grant and intelligence aggregation platform is not conceptually novel, and search/retrieval systems are long-established. The more distinctive part is the longevity-specific combination of verified funding discovery, dossiers, project/company/concept ratings, private team workspaces, and API-oriented field intelligence. The evidence supports this positioning, but not that the underlying technical approach is frontier-level.
Falsifiability70
The central claim is quite testable: compare Eternal Search against manual search or generic tools on missed opportunities, duplicate rate, stale deadlines, broken URLs, relevance precision, and time saved. The project itself states concrete objectives such as verified deadlines, working submission URLs, zero duplicate entries, and scaling personalized matching to 50+ teams. The weakness is that the evidence does not show those tests have been run.
Breakthrough panel
Mechanism novelty38
The mechanism is an applied combination of existing search, extraction, verification, deduplication, private workspaces, relevance scoring, and API access. That could be useful infrastructure, but the fetched evidence supports an improved funding-intelligence workflow rather than a fundamentally new technical mechanism.
Effect size5 claimed lower-bound hours saved per research team per week34
The strongest claimed effect is operational: reducing manual funding search from 5-15 hours per week to minutes and avoiding duplicates, dead deadlines, and irrelevant calls. This would matter for small teams, but the claim is self-reported by the project and no independent benchmark of recall, precision, freshness, or time saved is provided. It has no direct demonstrated lifespan effect.
Cross-domain impact47
The platform is already framed beyond longevity, covering science, medicine, engineering, arts, grants, fellowships, infrastructure funding, investors, and events. The public catalogue also shows non-longevity and adjacent opportunities. Current cross-domain impact is plausible as discovery infrastructure, but evidence is mostly platform-owned and does not show adoption outcomes across independent institutions.
Future opening potential55
If the system becomes trusted, it could support machine-readable funding intelligence, field mapping, project ratings, API-based institutional workflows, and funder coordination. The evidence shows a roadmap with API access, private team spaces, shared discovery data, and re-rated field intelligence, but the ambitious field-level operating-layer thesis remains unvalidated.
Time horizon~1 yr72
The project is live now, with public metrics including 646 catalogue grants, 53 open grants, 21 companies rated, 2 projects rated, 94 concepts, 7 upcoming events, and current news/grant pages. Basic demonstrability is therefore near-term; the harder validation of accuracy and user time savings could be tested within roughly one year.
Paradigm shift signal31
If it works well, Eternal Search would challenge the assumption that funding discovery must remain a manual, fragmented, spreadsheet-driven process. That is a meaningful workflow shift, but not a scientific paradigm shift in aging biology or medicine; the evidence supports infrastructure utility more than a new model of longevity intervention.
Investor panel
Most attractive
Regulatory pathway clarity (88)There is no FDA/EMA therapeutic regulatory pathway because this is a funding and intelligence platform, not a drug, device, diagnostic, or clinical intervention. The main compliance surface is data/privacy and API operations. The privacy page shows awareness of API logging, personal data, non-sale of data, and access/deletion requests, but no formal compliance certification is evidenced.
Most concerning
Customer validation signal (32)The product is live and claims to serve research teams, but the evidence does not show paying customers, pilots, LOIs, renewal data, named institutions, press from end users, or API usage counts. The stated objective to scale to 50+ teams reads as a goal rather than validation already achieved. Catalogue usage and public availability are positive but weaker than outside-team demand proof.
Addressable market$2B58
The problem is real and broad enough: research teams, scientists, innovators, foundations, and capital allocators all face fragmented funding and field-intelligence workflows. Evidence supports a multi-sided funding-discovery and intelligence product with grants, fellowships, infrastructure funding, investors, events, public catalogue, API, and enterprise team licences. However, no fetched evidence gives an independent TAM estimate, paid-seat count, pricing, or budget-owner penetration, so the market score is capped. Raw TAM is a best-effort SaaS/API estimate for research-funding intelligence rather than a cited analyst number.
Defensibility42
The defensibility case is mainly operational data quality: verified deadlines, deduplication, structured dossiers, semantic relevance scoring, shared discovery data, private workspaces, and API access. That can compound if the dataset stays fresher than alternatives. But the fetched evidence does not show owned IP, exclusive data rights, proprietary contracts, locked-in institutional workflows, or audited performance. Generic search and AI-assisted scraping are replicable, and one unrelated abandoned search patent does not appear to belong to this project.
Team execution capacity54
There is evidence of a shipped, live product: public pages show 646 grants, 53 open grants, 21 companies rated, 2 projects rated, 94 concepts, 7 events, news items, grant pages, API-related privacy language, and a named co-founder/platform lead in the internal project evidence. That supports execution above concept stage. The score remains moderate because the evidence does not show prior comparable exits, institutional deployments, engineering team depth, uptime, API usage, or customer retention.
Founder skin in the game35
The project is operated by Open Longevity (California 501(c)(3) nonprofit) and seeks grant support for server, compute, data access, engineering capacity, and operational continuity. That suggests mission commitment and public-good orientation, but the fetched evidence does not show founder capital invested, low salary, personal guarantees, equity/cash tradeoffs, or other hard skin-in-game signals. Public reputation risk exists because the platform is live, but the evidence is thin.
Customer validation signal32
The product is live and claims to serve research teams, but the evidence does not show paying customers, pilots, LOIs, renewal data, named institutions, press from end users, or API usage counts. The stated objective to scale to 50+ teams reads as a goal rather than validation already achieved. Catalogue usage and public availability are positive but weaker than outside-team demand proof.
Burn to breakeven$8M72
This is software infrastructure, not therapeutics or hardware. The project needs server/compute, data access, engineering, and operations rather than clinical trials or capex-heavy commercialization. Using the supplied SaaS benchmark of roughly $5M-$30M to break even, I estimate $8M to self-sustaining because it already has a live product and public catalogue but still appears grant-dependent and needs engineering continuity.
Time to value12 mo76
Time to value is relatively short because the platform is already live and has a stated premium API and enterprise licence revenue path. The value event is revenue or institutional/API adoption, not a clinical readout. I estimate 12 months to meaningful revenue validation from the current stage, while noting no fetched evidence proves current paid revenue.
Regulatory pathway clarity88
There is no FDA/EMA therapeutic regulatory pathway because this is a funding and intelligence platform, not a drug, device, diagnostic, or clinical intervention. The main compliance surface is data/privacy and API operations. The privacy page shows awareness of API logging, personal data, non-sale of data, and access/deletion requests, but no formal compliance certification is evidenced.
Competitive freedom45
The project has a differentiated longevity-focused positioning and claims to combine verified grants, field ratings, investor intelligence, dossiers, team workspaces, and API access. Still, the broad market includes generic search engines, grant portals, institutional research offices, commercial grant-search tools, CRMs, and increasingly easy AI-assisted scraping. The fetched evidence does not show why competitors cannot match the workflow or dataset quality.
Asymmetric upside10×55
The home-run case is a trusted machine-readable intelligence layer for longevity funding, project ratings, field mapping, and institutional API workflows. That could be strategically valuable if it becomes the default map for a growing scientific ecosystem. But the evidence supports a small live platform, not a network-effect monopoly or high-margin enterprise business yet. I use a 10x best-case multiple, consistent with research tool/services upside rather than biotech-platform M&A upside.
| Deal name▲ | Acquirer▲ | Target▲ | Indication▲ | Tech/modality▲ | Year▼ | Value▲ | Multiple▲ | Type▲ | Source▲ |
|---|
| Merck-Infinimmune antibody discovery collaboration | Merck | Infinimmune | Undisclosed therapeutic antibody targets | Human memory B-cell antibody discovery platform with AI antibody refinement | 2026 | $838.0m | - | license | ↗ |
| Chugai-Gero age-related disease AI platform collaboration | Chugai Pharmaceutical | Gero | Age-related diseases and potentially aging mechanisms | AI target-discovery platform trained on medical records | 2025 | $1.0b | - | license | ↗ |
Cost to commercialize$3M82
Commercial launch capital is low because the product is already public and software-based. Remaining commercialization work appears to be engineering, compute, data access, API hardening, and enterprise/team workflow development. I estimate $3M to first commercial product maturity, separate from $8M to breakeven, because it does not require trials, manufacturing, lab infrastructure, or hardware deployment.
★ AI estimate from available evidence — click any star for rationale.